Adam M Brufsky, MD, PhD, discusses some of the key topics and data included in a webcast activity for examining the clinical and cost implications of HER-positive breast cancer care in the value-based care era.
A recent study found that diagnosis-to-treatment interval may be linked with prognostic clinical factors and event-free survival in newly diagnosed diffuse large B-cell lymphoma.
Real-World Study Determines Effectiveness of Targeted Therapy for Relapsed, Refractory B-Cell Malignancy
A recent study demonstrated the real-world effectiveness and tolerability of a targeted agent for the treatment of relapsed or refractory mantle cell lymphoma.
Dawn Holcombe, MBA, FACMPE, ACHE, explains why private payers are making the transition from traditional reimbursement models to value-based models at a slow pace and how OCM performance results may impact this transition.
Many physicians still mistakenly believe that hospice and palliative medicine are one and the same, according to Timothy W Holder, MD, medical director, supportive care and survivorship, Cancer Treatment Centers of America.
Thomas Marsland, MD, medical oncology, St Joseph Health (Petaluma, CA), discusses the many considerations related to initial therapy, transplantation, maintenance, and salvage therapy for patients with multiple myeloma.
In a study to test the efficacy of the ASCO Patient-Centered Oncology Payment model, hospitalizations during the active treatment period for ovarian cancer were expected to decrease by what percentage?
According to a presentation at the SGO Annual Meeting, which adverse event associated with PARP inhibitor administration should be a top concern for oncologists?
Referral of newly diagnosed adolescent patients with acute lymphoblastic leukemia to pediatric and National Cancer Institute-designated centers should be strongly recommended.
Medicare will pay hospitals close to its standard mark-up rate for administering cell therapy Yescarta for cancer outpatients, who will have a co-payment of nearly $80,000.